Patents by Inventor Hiroyasu Takemoto
Hiroyasu Takemoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11890347Abstract: A pH-responsive polymer formed of a biocompatible polymer to which a group which is electrically neutral under pH environments of more than 7 and which changes to be cationic at pH 7 or less is bonded.Type: GrantFiled: December 5, 2017Date of Patent: February 6, 2024Assignee: Tokyo Institute of TechnologyInventors: Nobuhiro Nishiyama, Hiroyasu Takemoto, Abdul-Hackam Ranneh, Keishiro Tomoda, Takahiro Nomoto, Makoto Matsui
-
Patent number: 11707530Abstract: The present invention pertains to a ligand that contains a plurality of groups represented by formula (1) and is capable of multivalently binding to a glutamine transporter expressed in excess in a cancer cell compared to a normal cell.Type: GrantFiled: August 17, 2017Date of Patent: July 25, 2023Assignees: TOKYO INSTITUTE OF TECHNOLOGY, OSAKA UNIVERSITYInventors: Nobuhiro Nishiyama, Hiroyasu Takemoto, Takahiro Nomoto, Keishiro Tomoda, Makoto Matsui, Naoki Yamada, Yuto Honda, Hideshi Ishii, Masaki Mori, Masamitsu Konno
-
Patent number: 11555082Abstract: The present invention pertains to: a p-boronophenylalanine derivative that comprises a polymer to which a group represented by formula (I) is linked directly or via a linker; a composition containing same; and a kit for producing said derivative and composition.Type: GrantFiled: February 19, 2019Date of Patent: January 17, 2023Assignee: TOKYO INSTITUTE OF TECHNOLOGYInventors: Nobuhiro Nishiyama, Takahiro Nomoto, Yukiya Inoue, Ying Yao, Kaito Kanamori, Hiroyasu Takemoto, Makoto Matsui, Keishiro Tomoda
-
Publication number: 20220387609Abstract: A bio-related substance bonded to a branched and degradable polyethylene glycol derivative that is degraded in the cells represented by the following formula (A): wherein each symbol is as defined in the present specification, is provided by the present invention.Type: ApplicationFiled: March 26, 2020Publication date: December 8, 2022Applicants: NOF CORPORATION, TOKYO INSTITUTE OF TECHNOLOGYInventors: Hiroki YOSHIOKA, Kazuki OSAKAMA, Mika HAMURA, Takanori INABA, Nobuhiro NISHIYAMA, Makoto MATSUI, Hiroyasu TAKEMOTO, Takahiro NOMOTO, Xiaohang SUN
-
Publication number: 20220265836Abstract: A complex is provided comprising a conjugate in which a polymer having a boronic acid group and a compound having a diol structure are bonded, and a substance that is complexed with the conjugate.Type: ApplicationFiled: May 29, 2020Publication date: August 25, 2022Applicants: TOKYO INSTITUTE OF TECHNOLOGY, KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTIONInventors: Nobuhiro Nishiyama, Yuto Honda, Takahiro Nomoto, Hiroyasu Takemoto, Makoto Matsui, Hiroaki Kinoh, Kazunori Kataoka, Xueying Liu, Anjaneyulu Dirisala
-
Publication number: 20220211646Abstract: A conjugate is provided in which a deferoxamine-type compound, which is at least one compound selected from the group consisting of deferoxamine or an ion or salt thereof, and a derivative thereof, and a biocompatible polymer are conjugated, where the biocompatible polymer contains a first biocompatible polymer chain and a second biocompatible polymer chain that is different from the first biocompatible polymer chain.Type: ApplicationFiled: April 23, 2020Publication date: July 7, 2022Inventors: Nobuhiro NISHIYAMA, Takahiro NOMOTO, Kana KOHMOTO, Hiroyasu TAKEMOTO, Makoto MATSUI
-
Patent number: 11376266Abstract: The present invention is directed to provide antitumor agent including water-soluble sulfasalazine as an active ingredient. Antitumor agents were obtained with, as the water-soluble sulfasalazine, a PEG-modified sulfasalazine represented by the following formula: wherein an average value of n is 4 or larger and 1136 or smaller.Type: GrantFiled: January 5, 2017Date of Patent: July 5, 2022Assignees: Keio University, Tokyo Institute of TechnologyInventors: Hideyuki Saya, Osamu Nagano, Kenji Tsuchihashi, Kentaro Suina, Nobuhiro Nishiyama, Hiroyasu Takemoto, Takahiro Nomoto, Makoto Matsui, Keishiro Tomoda, Naoki Yamada, Tsukasa Nishimori
-
Publication number: 20220153992Abstract: An intracellularly degraded branched and degradable polyethylene glycol derivative represented by the following formula (1): wherein each symbol is as defined in the present specification, that is used for modifying bio-related substances is provided by the present invention.Type: ApplicationFiled: March 26, 2020Publication date: May 19, 2022Applicants: NOF CORPORATION, TOKYO INSTITUTE OF TECHNOLOGYInventors: Hiroki YOSHIOKA, Kazuki OSAKAMA, Mika HAMURA, Takanori INABA, Nobuhiro NISHIYAMA, Makoto MATSUI, Hiroyasu TAKEMOTO, Takahiro NOMOTO, Xiaohang SUN
-
Publication number: 20210308271Abstract: The present invention pertains to a ligand that contains a plurality of groups represented by formula (1) and is capable of multivalently binding to a glutamine transporter expressed in excess in a cancer cell compared to a normal cell.Type: ApplicationFiled: August 17, 2017Publication date: October 7, 2021Applicants: TOKYO INSTITUTE OF TECHNOLOGY, OSAKA UNIVERISTYInventors: Nobuhiro Nishiyama, Hiroyasu Takemoto, Takahiro Nomoto, Keishiro Tomoda, Makoto Matsui, Naoki Yamada, Yuto Honda, Hideshi Ishii, Masaki Mori, Masamitsu Konno
-
Patent number: 11020418Abstract: A unit structure-type pharmaceutical composition includes a single nucleic acid, such as an antisense nucleic acid, electrostatically bound to a single block copolymer having a cationic polyamino acid segment and a hydrophilic polymer chain segment. The negative charges of the nucleic acid are counterbalanced, at least substantially, by the positive charges of the cationic polyamino acid segment such that the pharmaceutical composition is electrically neutral or nearly electrically neutral. Further, the nucleic acid is covered with the hydrophilic polymer chain segment. The block copolymer thereby improves the blood retention capability of the nucleic acids.Type: GrantFiled: October 5, 2017Date of Patent: June 1, 2021Assignees: NANOCARRIER CO., LTD., THE UNIVERSITY OF TOKYOInventors: Kazunori Kataoka, Kanjiro Miyata, Nobuhiro Nishiyama, Kensuke Osada, Sumiyo Watanabe, Shigeto Fukushima, Hiroyuki Chaya, Hiroyasu Takemoto, Yasuki Kato
-
Publication number: 20210147624Abstract: The invention provides a high-molecular-weight polyethylene glycol derivative that does not cause vacuolation of cells. The degradable polyethylene glycol derivative is represented by the following formula (1): wherein m is 1-7, n1 and n2 are each independently 45-682, p is 1-4, R is an alkyl group having 1-4 carbon atoms, Z is an oligopeptide with 2-8 residues composed of neutral amino acids excluding cysteine, Q is a residue of a compound having 2-5 active hydrogens, X is a functional group capable of reacting with a bio-related substance, and L1, L2, L3, L4 and L5 are each independently a single bond or a divalent spacer.Type: ApplicationFiled: March 29, 2019Publication date: May 20, 2021Applicants: NOF Corporation, Tokyo Institute of TechnologyInventors: Hiroki YOSHIOKA, Masaki KAMIYA, Yuji YAMAMOTO, Midori HIRAI, Akiko SASAKI, Nobuhiro NISHIYAMA, Makoto MATSUI, Hiroyasu TAKEMOTO, Kazuki MIYAUCHI, Takahiro NOMOTO, Keishiro TOMODA
-
Publication number: 20210046190Abstract: An object to be achieved by the present invention is to provide a technique for enhancing the anticancer effect of ubenimex; in particular, enhancing its anticancer effect on solid cancer. This object can be achieved by a compound containing a chain structure in which a plurality of ubenimex molecules is linked to a chain polymer.Type: ApplicationFiled: January 30, 2019Publication date: February 18, 2021Inventors: Masaki MORI, Hideshi ISHII, Masamitsu KONNO, Hidetoshi EGUCHI, Naotsugu HARAGUCHI, Reishi TOSHIYAMA, Nobuhiro NISHIYAMA, Hiroyasu TAKEMOTO
-
Publication number: 20210040244Abstract: The present invention pertains to: a p-boronophenylalanine derivative that comprises a polymer to which a group represented by formula (I) is linked directly or via a linker; a composition containing same; and a kit for producing said derivative and composition.Type: ApplicationFiled: February 19, 2019Publication date: February 11, 2021Inventors: Nobuhiro NISHIYAMA, Takahiro NOMOTO, Yukiya INOUE, Ying YAO, Kaito KANAMORI, Hiroyasu TAKEMOTO, Makoto MATSUI, Keishiro TOMODA
-
Publication number: 20210023231Abstract: The invention provides a bio-related substance bonded to a high-molecular-weight polyethylene glycol derivative that does not cause vacuolation of cells. The bio-related substance bonded to a degradable polyethylene glycol derivative is represented by the formula (A): wherein m is 1-7, n1 and n2 are each independently 45-682, p is 1-4, R is an alkyl group having 1-4 carbon atoms, Z is an oligopeptide with 2-8 residues composed of neutral amino acids excluding cysteine, Q is a residue of a compound having 2-5 active hydrogens, D is the bio-related substance, L1, L2, L3, L4 and L5 are each independently a single bond or a divalent spacer, and y is 1-40.Type: ApplicationFiled: March 29, 2019Publication date: January 28, 2021Applicants: NOF CORPORATION, TOKYO INSTITUTE OF TECHNOLOGYInventors: Hiroki YOSHIOKA, Masaki KAMIYA, Yuji YAMAMOTO, Midori HIRAI, Akiko SASAKI, Nobuhiro NISHIYAMA, Makoto MATSUI, Hiroyasu TAKEMOTO, Kazuki MIYAUCHI, Takahiro NOMOTO, Keishiro TOMODA
-
Publication number: 20200261476Abstract: The present invention is directed to provide antitumor agent including water-soluble sulfasalazine as an active ingredient. Antitumor agents were obtained with, as the water-soluble sulfasalazine, a PEG-modified sulfasalazine represented by the following formula: wherein an average value of n is 4 or larger and 1136 or smaller.Type: ApplicationFiled: January 5, 2017Publication date: August 20, 2020Applicants: KEIO UNIVERSITY, TOKYO INSTITUTE OF TECHNOLOGY, TOKYO INSTITUTE OF TECHNOLOGYInventors: Hideyuki SAYA, Osamu NAGANO, Kenji TSUCHIHASHI, Kentaro SUINA, Nobuhiro NISHIYAMA, Hiroyasu TAKEMOTO, Takahiro NOMOTO, Makoto MATSUI, Keishiro TOMODA, Naoki YAMADA, Tsukasa NISHIMORI
-
Publication number: 20200069807Abstract: A pH-responsive polymer formed of a biocompatible polymer to which a group which is electrically neutral under pH environments of more than 7 and which changes to be cationic at pH 7 or less is bonded.Type: ApplicationFiled: December 5, 2017Publication date: March 5, 2020Inventors: Nobuhiro Nishiyama, Hiroyasu Takemoto, Abdul-Hackam Ranneh, Keishiro Tomoda, Takahiro Nomoto, Makoto Matsui
-
Publication number: 20180153920Abstract: A unit structure consists of a single nucleic acid having a length of 10 to 30 bases, and a single block copolymer having a cationic polyamino acid segment and a hydrophilic polymer chain segment. In this unit structure: (i) a difference between a total of positive charges derived from cationic groups of the cationic polyamino acid segment and a total of negative charges derived from the nucleic acid in the unit structure falls within a range of ±10% of the total of the negative charges derived from the nucleic acid, (ii) the hydrophilic polymer chain segment comprises polyethylene glycol, (iii) the polyethylene glycol has a radius of inertia (Rg) equal to or longer than the length of the nucleic acid, and (iv) the cationic polyamino acid segment is bound to the nucleic acid via electrostatic bonds.Type: ApplicationFiled: January 25, 2018Publication date: June 7, 2018Inventors: Kazunori KATAOKA, Kanjiro MIYATA, Nobuhiro NISHIYAMA, Kensuke OSADA, Sumiyo WATANABE, Shigeto FUKUSHIMA, Hiroyuki CHAYA, Hiroyasu TAKEMOTO, Yasuki KATO
-
Publication number: 20180042955Abstract: A unit structure-type pharmaceutical composition includes a single nucleic acid, such as an antisense nucleic acid, electrostatically bound to a single block copolymer having a cationic polyamino acid segment and a hydrophilic polymer chain segment. The negative charges of the nucleic acid are counterbalanced, at least substantially, by the positive charges of the cationic polyamino acid segment such that the pharmaceutical composition is electrically neutral or nearly electrically neutral. Further, the nucleic acid is covered with the hydrophilic polymer chain segment. The block copolymer thereby improves the blood retention capability of the nucleic acids.Type: ApplicationFiled: October 5, 2017Publication date: February 15, 2018Inventors: Kazunori KATAOKA, Kanjiro MIYATA, Nobuhiro NISHIYAMA, Kensuke OSADA, Sumiyo WATANABE, Shigeto FUKUSHIMA, Hiroyuki CHAYA, Hiroyasu TAKEMOTO, Yasuki KATO
-
Patent number: 9808480Abstract: A unit structure-type pharmaceutical composition includes at least one nucleic acid, such as siRNA, electrostatically bound to at least one block copolymer having a cationic polyamino acid segment and a hydrophilic polymer chain segment. The negative charge(s) of the nucleic acid are counterbalanced, at least substantially, by the positive charge(s) of the cationic polyamino acid segment such that the pharmaceutical composition is electrically neutral or nearly electrically neutral. Further, the nucleic acid is covered with the hydrophilic polymer chain segment(s). The at least one block copolymer thereby improves the blood retention capability of the nucleic acid(s).Type: GrantFiled: April 30, 2013Date of Patent: November 7, 2017Assignees: NANOCARRIER CO., LTD., THE UNIVERSITY OF TOKYOInventors: Kazunori Kataoka, Kanjiro Miyata, Nobuhiro Nishiyama, Kensuke Osada, Sumiyo Watanabe, Shigeto Fukushima, Hiroyuki Chaya, Hiroyasu Takemoto, Yasuki Kato
-
Publication number: 20150080454Abstract: A unit structure-type pharmaceutical composition includes at least one nucleic acid, such as siRNA, electrostatically bound to at least one block copolymer having a cationic polyamino acid segment and a hydrophilic polymer chain segment. The negative charge(s) of the nucleic acid are counterbalanced, at least substantially, by the positive charge(s) of the cationic polyamino acid segment such that the pharmaceutical composition is electrically neutral or nearly electrically neutral. Further, the nucleic acid is covered with the hydrophilic polymer chain segment(s). The at least one block copolymer thereby improves the blood retention capability of the nucleic acid(s).Type: ApplicationFiled: April 30, 2013Publication date: March 19, 2015Applicants: NANOCARRIER CO., LTD., THE UNIVERSITY OF TOKYOInventors: Kazunori Kataoka, Kanjiro Miyata, Nobuhiro Nishiyama, Kensuke Osada, Sumiyo Watanabe, Shigeto Fukushima, Hiroyuki Chaya, Hiroyasu Takemoto, Yasuki Kato